@OzmosiHealth Ozmosi

Ozmosi posts on X about more info, announces, health, the first the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

[--] Week [------] -19%
[--] Month [------] -26%
[--] Months [-------] +19%
[--] Year [---------] +23%

Mentions: [--] #

[--] Week [---] +1.10%
[--] Month [---] +5.30%
[--] Months [-----] +6%
[--] Year [-----] -0.75%

Followers: [-----] #

[--] Week [-----] -0.10%
[--] Month [-----] +0.30%
[--] Months [-----] +14%
[--] Year [-----] +43%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 55.6% countries 4.33% cryptocurrencies 4.33% finance 0.72% technology brands 0.36%

Social topic influence more info #809, announces 3.25%, health 2.89%, the first 2.89%, canada 2.53%, $xbi #50, $cgtx 2.17%, $ibb 1.81%, $xph 1.81%, $pph 1.81%

Top accounts mentioned or mentioned by @wallstreet_dawg

Top Social Posts

Top posts by engagements in the last [--] hours

"THE PLAN Biotech $XBI Investor in [----] Wake up at 6:45 AM and immediately check whether an FDA panel / departure / appointment destroyed your net worth overnight. It usually did. Tell yourself youre going to diversify this year. Then put 40% of your portfolio into a company with [--] employees and a molecule that only worked on three mice in Finland. Pretend you understand every mechanism of action. Google What is a ligand at least once a week. Read a 278-page clinical trial PDF like its the Dead Sea Scrolls even though all you really comprehend is the table with the green arrows pointing up."
X Link 2025-12-08T19:08Z [----] followers, 13.4K engagements

"$GMAB Genmab Announces Net Sales of DARZALEX (daratumumab) for [----] More Info: https://pryzm.ozmosi.com/product/3879 https://pryzm.ozmosi.com/product/3879"
X Link 2026-01-21T14:02Z [----] followers, [---] engagements

"$COX Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX [---] More Info: https://pryzm.ozmosi.com/product/23864 https://pryzm.ozmosi.com/product/23864"
X Link 2026-02-16T14:02Z [----] followers, [---] engagements

"$ELAB Elevai Labs obtains exclusive license for two muscle loss prevention assets plans to develop in combination with GLP-1 obesity treatments. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/11908 https://pryzm.ozmosi.com/product/11908"
X Link 2024-05-01T13:02Z [----] followers, [---] engagements

"$ELAB Elevai Labs obtains exclusive license for two muscle loss prevention assets to develop along with GLP-1 obesity treatments. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/11908 https://pryzm.ozmosi.com/product/11908"
X Link 2024-05-01T13:47Z [----] followers, [---] engagements

"$ELAB Elevai Labs secures rights to two muscle loss prevention assets to be combined with GLP-1 obesity treatments. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/11908 https://pryzm.ozmosi.com/product/11908"
X Link 2024-05-01T14:02Z [----] followers, [---] engagements

"$AMLX Positive long-term results from Phase [--] HELIOS trial of AMX0035 in Wolfram syndrome announced by Amylyx Pharmaceuticals. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/14195 https://pryzm.ozmosi.com/product/14195"
X Link 2025-05-12T11:32Z [----] followers, [---] engagements

"$EVAX Evaxion Biotech announced they will present Phase [--] Melanoma results on 2025-10-17 for EVX-01 More Info: https://pryzm.ozmosi.com/product/25443 https://pryzm.ozmosi.com/product/25443"
X Link 2025-10-14T21:49Z [----] followers, [---] engagements

"$ZLAB -1.78% today as Zai Lab Announces Updated Phase [--] Data for Zocilurtatug Pelitecan (formerly ZL-1310) Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer and Initiation of Global Phase [--] Registrational Study More Info: https://pryzm.ozmosi.com/product/30501 https://pryzm.ozmosi.com/product/30501"
X Link 2025-10-24T14:09Z [----] followers, [---] engagements

"$XLO +4.15% today as Xilio Therapeutics to Present Phase [--] Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting More Info: https://pryzm.ozmosi.com/product/23341 https://pryzm.ozmosi.com/product/23341"
X Link 2025-10-30T13:56Z [----] followers, [---] engagements

"$NRIX -6.08% today as Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling More Info: https://pryzm.ozmosi.com/product/24725 https://pryzm.ozmosi.com/product/24725"
X Link 2025-11-07T16:41Z [----] followers, [---] engagements

"$NRIX Nurix Therapeutics presented P1 Oncology Solid Tumor Unspecified results on 2025-11-07 for NX-1607 More Info: https://pryzm.ozmosi.com/product/24725.0 https://pryzm.ozmosi.com/product/24725.0"
X Link 2025-11-10T18:46Z [----] followers, [---] engagements

"$CGTX -5.22% today as Cognition Therapeutics Completes Enrollment in Phase [--] Study of Zervimesine (CT1812) in Early Alzheimer's Disease More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"
X Link 2025-11-13T16:01Z [----] followers, [---] engagements

"$HRMY +0.64% today as Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation More Info: https://pryzm.ozmosi.com/product/1714 https://pryzm.ozmosi.com/product/1714"
X Link 2025-11-24T14:58Z [----] followers, [---] engagements

"$NRSN -1.40% today as NeuroSense Receives FDA Clearance to Initiate Pivotal Phase [--] Trial for PrimeC in ALS More Info: https://pryzm.ozmosi.com/product/28154 https://pryzm.ozmosi.com/product/28154"
X Link 2025-11-24T21:10Z [----] followers, [---] engagements

"$CGEM -6.60% today as Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049 a Novel FLT3xCD3 T Cell Engager in Relapsed/Refractory Acute Myeloid Leukemia More Info: https://pryzm.ozmosi.com/product/24765 https://pryzm.ozmosi.com/product/24765"
X Link 2025-12-01T15:46Z [----] followers, [---] engagements

"$CGTX -5.49% today as Cognition Therapeutics Presents Phase [--] Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"
X Link 2025-12-01T15:46Z [----] followers, [---] engagements

"$VALN Valneva presented P2 Lyme Disease results on 2025-11-26 for VLA-15 More Info: https://pryzm.ozmosi.com/product/17682 https://pryzm.ozmosi.com/product/17682"
X Link 2025-12-01T19:35Z [----] followers, [---] engagements

"$ABOS Acumen Pharmaceuticals presented P2 Alzheimer Disease results on 2025-12-02 for Sabirnetug More Info: https://pryzm.ozmosi.com/product/22482 https://pryzm.ozmosi.com/product/22482"
X Link 2025-12-03T20:59Z [----] followers, [---] engagements

"$ORIC Oric presented P1 Oncology Solid Tumor Unspecified results on 2025-12-04 for Enozertinib More Info: https://pryzm.ozmosi.com/product/25434 https://pryzm.ozmosi.com/product/25434"
X Link 2025-12-05T20:39Z [----] followers, [---] engagements

"$ZLAB -2.74% today as Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503 an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis More Info: https://pryzm.ozmosi.com/product/33412 https://pryzm.ozmosi.com/product/33412"
X Link 2025-12-08T15:15Z [----] followers, [---] engagements

"$BMEA Biomea Fusion presented P2 Type [--] Diabetes results on 2025-12-05 for Icovamenib More Info: https://pryzm.ozmosi.com/product/23569 https://pryzm.ozmosi.com/product/23569"
X Link 2025-12-08T21:23Z [----] followers, [---] engagements

"$BRNS +7.75% today as Barinthus Bio Announces Update on Phase [--] AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease More Info: https://pryzm.ozmosi.com/product/27012 https://pryzm.ozmosi.com/product/27012"
X Link 2025-12-10T14:42Z [----] followers, [---] engagements

"$DERM Journey Medical presented P1 Rosacea results on 2025-12-10 for DFD-29 More Info: https://pryzm.ozmosi.com/product/25524 https://pryzm.ozmosi.com/product/25524"
X Link 2025-12-11T18:33Z [----] followers, [---] engagements

"$TNYA -2.50% today as Tenaya Therapeutics Reports Positive Interim Data from Cohort [--] of RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC More Info: https://pryzm.ozmosi.com/product/25601 https://pryzm.ozmosi.com/product/25601"
X Link 2025-12-11T22:01Z [----] followers, [---] engagements

"$TNYA -2.50% today as Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy More Info: https://pryzm.ozmosi.com/product/26351 https://pryzm.ozmosi.com/product/26351"
X Link 2025-12-11T22:01Z [----] followers, [---] engagements

"$MLYS +6.60% today as Mineralys Therapeutics' Phase [--] Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup More Info: https://pryzm.ozmosi.com/product/23111 https://pryzm.ozmosi.com/product/23111"
X Link 2025-12-12T18:38Z [----] followers, [---] engagements

"$TNYA Tenaya Therapeutics presented P1 Arrhythmogenic Right Ventricular Dysplasia results on 2025-12-11 for TN-401 More Info: https://pryzm.ozmosi.com/product/25601 https://pryzm.ozmosi.com/product/25601"
X Link 2025-12-12T18:38Z [----] followers, [---] engagements

"$MLYS Mineralys Therapeutics presented P3 Resistant Hypertension results on 2025-12-12 for Lorundrostat More Info: https://pryzm.ozmosi.com/product/23111 https://pryzm.ozmosi.com/product/23111"
X Link 2025-12-15T21:11Z [----] followers, [---] engagements

"$HOWL Werewolf Therapeutics announced they will present P1 Oncology Solid Tumor Unspecified results in 1H26 for WTX-124 More Info: https://pryzm.ozmosi.com/product/25073 https://pryzm.ozmosi.com/product/25073"
X Link 2025-12-19T19:12Z [----] followers, [---] engagements

"$HOWL Werewolf Therapeutics announced they will present P1 Oncology Solid Tumor Unspecified results in 1H26 for WTX-330 More Info: https://pryzm.ozmosi.com/product/25074 https://pryzm.ozmosi.com/product/25074"
X Link 2025-12-19T19:12Z [----] followers, [---] engagements

"$COYA as Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA [---] ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) More Info: https://pryzm.ozmosi.com/product/31651 https://pryzm.ozmosi.com/product/31651"
X Link 2025-12-23T15:19Z [----] followers, [---] engagements

"$BCAB Alert BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) More Info: https://pryzm.ozmosi.com/product/20435 https://pryzm.ozmosi.com/product/20435"
X Link 2025-12-31T14:02Z [----] followers, [---] engagements

"$MPLT MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis More Info: https://pryzm.ozmosi.com/product/31046 https://pryzm.ozmosi.com/product/31046"
X Link 2026-01-05T14:03Z [----] followers, [---] engagements

"$COYA Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA [---] for the Treatment of Frontotemporal Dementia (FTD) More Info: https://pryzm.ozmosi.com/product/31651 https://pryzm.ozmosi.com/product/31651"
X Link 2026-01-05T14:03Z [----] followers, [---] engagements

"$GHRS GH Research Announces FDA Lifts Clinical Hold on GH001 Clearing Path for Global Phase [--] Initiation in [----] More Info: https://pryzm.ozmosi.com/product/26166 https://pryzm.ozmosi.com/product/26166"
X Link 2026-01-05T14:03Z [----] followers, [---] engagements

"$APGE Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777) its Potentially Best-in-Class Anti-IL-13 Antibody in Patients with Mild-to-Moderate Asthma and Highlights [----] Anticipated Milestones and Outlook More Info: https://pryzm.ozmosi.com/product/31038 https://pryzm.ozmosi.com/product/31038"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$GANX Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 More Info: https://pryzm.ozmosi.com/product/23956 https://pryzm.ozmosi.com/product/23956"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$CGTX Cognition Therapeutics Publishes Phase [--] Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$ZLAB Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO (repotrectinib) for Patients with NTRK-Positive Solid Tumors More Info: https://pryzm.ozmosi.com/product/16753 https://pryzm.ozmosi.com/product/16753"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$AKBA Akebia Therapeutics Announces First Patient Dosed in Phase [--] Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) More Info: https://pryzm.ozmosi.com/product/19874 https://pryzm.ozmosi.com/product/19874"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$CMPS Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360 More Info: https://pryzm.ozmosi.com/product/32500 https://pryzm.ozmosi.com/product/32500"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$NBP NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer More Info: https://pryzm.ozmosi.com/product/27189 https://pryzm.ozmosi.com/product/27189"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$TSHA Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome More Info: https://pryzm.ozmosi.com/product/26042 https://pryzm.ozmosi.com/product/26042"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$MIST Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency More Info: https://pryzm.ozmosi.com/product/825 https://pryzm.ozmosi.com/product/825"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$TIL Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco More Info: https://pryzm.ozmosi.com/product/24624 https://pryzm.ozmosi.com/product/24624"
X Link 2026-01-06T14:02Z [----] followers, [---] engagements

"$AUTL -0.53% today Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell Shuttle Platform More Info: https://pryzm.ozmosi.com/product/20457 https://pryzm.ozmosi.com/product/20457"
X Link 2026-01-06T15:02Z [----] followers, [---] engagements

"$AUTL -0.53% today Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell ShuttleTM Platform More Info: https://pryzm.ozmosi.com/product/20457 https://pryzm.ozmosi.com/product/20457"
X Link 2026-01-06T15:02Z [----] followers, [---] engagements

"$JAZZ Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit More Info: https://pryzm.ozmosi.com/product/21557 https://pryzm.ozmosi.com/product/21557"
X Link 2026-01-06T21:02Z [----] followers, [---] engagements

"$VERA -1.12% today Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy More Info: https://pryzm.ozmosi.com/product/2843 https://pryzm.ozmosi.com/product/2843"
X Link 2026-01-07T14:02Z [----] followers, [---] engagements

"$EXEL +3.09% today Exelixis and Natera to Collaborate on STELLAR-316 a Phase [--] Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer More Info: https://pryzm.ozmosi.com/product/19713 https://pryzm.ozmosi.com/product/19713"
X Link 2026-01-07T14:02Z [----] followers, [---] engagements

"$GNLX Genelux announced they will present P3 Ovarian Cancer results in 2H26 for Olvimulogene nanivacirepvec More Info: https://pryzm.ozmosi.com/product/21639 https://pryzm.ozmosi.com/product/21639"
X Link 2026-01-07T15:56Z [----] followers, [---] engagements

"$JBIO Jade Biosciences announced they will present P2 IgA Nephropathy results in YE27 for JADE-101 More Info: https://pryzm.ozmosi.com/product/34694 https://pryzm.ozmosi.com/product/34694"
X Link 2026-01-07T15:56Z [----] followers, [---] engagements

"$NMRA Neumora announced they will present P3 Depressive Disorder Major results in 2Q26 for Navacaprant More Info: https://pryzm.ozmosi.com/product/21674 https://pryzm.ozmosi.com/product/21674"
X Link 2026-01-07T15:56Z [----] followers, [---] engagements

"$ZBIO Zenas presented P3 IgG4-related Disease results on 2026-01-05 for Obexelimab More Info: https://pryzm.ozmosi.com/product/17691 https://pryzm.ozmosi.com/product/17691"
X Link 2026-01-07T15:56Z [----] followers, [---] engagements

"$CMPX Compass Therapeutics announced they will present P1 Non-Small-Cell Lung Cancer results in 2H26 for CTX-10726 More Info: https://pryzm.ozmosi.com/product/34847 https://pryzm.ozmosi.com/product/34847"
X Link 2026-01-07T18:20Z [----] followers, [---] engagements

"$DNLI Denali Therapeutics announced they will present P1 Mucopolysaccharidosis III results on 2026-02-03 for DNL-126 More Info: https://pryzm.ozmosi.com/product/29262 https://pryzm.ozmosi.com/product/29262"
X Link 2026-01-07T18:20Z [----] followers, [---] engagements

"$TSHA Taysha Gene Therapies announced they will present P1 Rett Syndrome results in 1H26 for Lonimecgene Renparvovec More Info: https://pryzm.ozmosi.com/product/26042 https://pryzm.ozmosi.com/product/26042"
X Link 2026-01-07T18:20Z [----] followers, [---] engagements

"$VRDN Viridian Therapeutics announced they will present P1 Healthy Volunteers results in 2H26 for VRDN-008 More Info: https://pryzm.ozmosi.com/product/32196 https://pryzm.ozmosi.com/product/32196"
X Link 2026-01-07T18:20Z [----] followers, [---] engagements

"$VRDN Viridian Therapeutics announced they will present P3 Thyroid Eye Disease results in 1Q26 for Elegrobart More Info: https://pryzm.ozmosi.com/product/25782 https://pryzm.ozmosi.com/product/25782"
X Link 2026-01-07T18:20Z [----] followers, [---] engagements

"$CGTX Cognition presented P2 Lewy Body Dementia results on 2026-01-06 for Zervimesine More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"
X Link 2026-01-07T18:20Z [----] followers, [---] engagements

"$RNAZ TRANSCODE THERAPEUTICS presented P0 Glioblastoma results on 2026-01-06 for TTX-MC138 More Info: https://pryzm.ozmosi.com/product/26544 https://pryzm.ozmosi.com/product/26544"
X Link 2026-01-07T18:20Z [----] followers, [---] engagements

"$RANI Rani Therapeutics Initiates Phase [--] Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen More Info: https://pryzm.ozmosi.com/product/33131 https://pryzm.ozmosi.com/product/33131"
X Link 2026-01-08T14:02Z [----] followers, [---] engagements

"$INKT MiNK Therapeutics and University of WisconsinMadison Announce Phase [--] Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease More Info: https://pryzm.ozmosi.com/product/23546 https://pryzm.ozmosi.com/product/23546"
X Link 2026-01-08T17:02Z [----] followers, [---] engagements

"$ALXO ALX Oncology announced they will present P1 Esophageal CancerNon-Small-Cell Lung CancerHead and Neck CancerColorectal CancerSquamous Cell Carcinoma results in 1H26 for ALX-2004 More Info: https://pryzm.ozmosi.com/product/34788 https://pryzm.ozmosi.com/product/34788"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$ALXO ALX Oncology announced they will present P2 Breast Cancer results in 3Q26 for Evorpacept More Info: https://pryzm.ozmosi.com/product/17751 https://pryzm.ozmosi.com/product/17751"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$ATAI ATAI Life Sciences announced they will present P2 Phobia Social results in 1Q26 for EMP-01 More Info: https://pryzm.ozmosi.com/product/26483 https://pryzm.ozmosi.com/product/26483"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$CLYM Climb Bio announced they will present P2 Membranous Nephropathy results in 2H26 for Budoprutug More Info: https://pryzm.ozmosi.com/product/34666 https://pryzm.ozmosi.com/product/34666"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$CGEM Cullinan Oncology announced they will present P1 Arthritis RheumatoidLupus Erythematosus Systemic results in 2Q26 for CLN-978 More Info: https://pryzm.ozmosi.com/product/26744 https://pryzm.ozmosi.com/product/26744"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$CGEM Cullinan Oncology announced they will present P1 Autoimmune Disease Unspecified results in 4Q26 for Velinotamig More Info: https://pryzm.ozmosi.com/product/25255 https://pryzm.ozmosi.com/product/25255"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$CGEM Cullinan Oncology announced they will present P1 Myelodysplastic Syndrome results in 2H26 for CLN-049 More Info: https://pryzm.ozmosi.com/product/24765 https://pryzm.ozmosi.com/product/24765"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$TRDA Entrada Therapeutics announced they will present P2 Muscular Dystrophy Duchenne results in 2Q26 for ENTR-601-44 More Info: https://pryzm.ozmosi.com/product/25129 https://pryzm.ozmosi.com/product/25129"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$ACRV Acrivon Therapeutics presented P1 Oncology Solid Tumor Unspecified results on 2026-01-08 for ACR-2316 More Info: https://pryzm.ozmosi.com/product/31119 https://pryzm.ozmosi.com/product/31119"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$COYA Coya Therapeutics presented P1 Frontotemporal Dementia results on 2026-01-08 for COYA-302 More Info: https://pryzm.ozmosi.com/product/31651 https://pryzm.ozmosi.com/product/31651"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$ELVN Enliven Therapeutics presented P1 Chronic Myeloid Leukemia results on 2026-01-08 for ELVN-001 More Info: https://pryzm.ozmosi.com/product/25409 https://pryzm.ozmosi.com/product/25409"
X Link 2026-01-09T18:20Z [----] followers, [---] engagements

"$SMMT Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC More Info: https://pryzm.ozmosi.com/product/21421 https://pryzm.ozmosi.com/product/21421"
X Link 2026-01-12T14:02Z [----] followers, [---] engagements

"$NRIX Nurix Therapeutics Outlines [----] Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases More Info: https://pryzm.ozmosi.com/product/24726 https://pryzm.ozmosi.com/product/24726"
X Link 2026-01-12T14:02Z [----] followers, [---] engagements

"$DTIL Precision BioSciences Sets Strategic Priorities for [----] Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy More Info: https://pryzm.ozmosi.com/product/32481 https://pryzm.ozmosi.com/product/32481"
X Link 2026-01-12T14:02Z [----] followers, [---] engagements

"$ACTU Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase [--] Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI [----] More Info: https://pryzm.ozmosi.com/product/22019 https://pryzm.ozmosi.com/product/22019"
X Link 2026-01-12T14:02Z [----] followers, [---] engagements

"$HRMY Harmony Biosciences Guides to Over $1 Billion in WAKIX Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation More Info: https://pryzm.ozmosi.com/product/1714 https://pryzm.ozmosi.com/product/1714"
X Link 2026-01-12T14:02Z [----] followers, [---] engagements

"$CABA IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms More Info: https://pryzm.ozmosi.com/product/27425 https://pryzm.ozmosi.com/product/27425"
X Link 2026-01-12T14:02Z [----] followers, [---] engagements

"$IMCR Immunocore announced they will present P1 Oncology Solid Tumor Unspecified results in 2H26 for IMC-P115C More Info: https://pryzm.ozmosi.com/product/32540 https://pryzm.ozmosi.com/product/32540"
X Link 2026-01-12T20:32Z [----] followers, [---] engagements

"$IMCR Immunocore announced they will present P1 Ovarian CancerNon-Small-Cell Lung Cancer results in 2H26 for Brenetafusp More Info: https://pryzm.ozmosi.com/product/22989 https://pryzm.ozmosi.com/product/22989"
X Link 2026-01-12T20:32Z [----] followers, [---] engagements

"$IMCR Immunocore announced they will present P3 Melanoma results in 2H26 for Tebentafusp More Info: https://pryzm.ozmosi.com/product/11241 https://pryzm.ozmosi.com/product/11241"
X Link 2026-01-12T20:32Z [----] followers, [---] engagements

"$MPLT MapLight Therapeutics announced they will present P2 Autism Spectrum Disorder results in 3Q26 for ML-004 More Info: https://pryzm.ozmosi.com/product/24000 https://pryzm.ozmosi.com/product/24000"
X Link 2026-01-12T20:32Z [----] followers, [---] engagements

"$MPLT MapLight Therapeutics announced they will present P2 Schizophrenia results in 3Q26 for ML-007 More Info: https://pryzm.ozmosi.com/product/31046 https://pryzm.ozmosi.com/product/31046"
X Link 2026-01-12T20:32Z [----] followers, [---] engagements

"$TNYA Tenaya Therapeutics announced they will present P1 Arrhythmogenic Right Ventricular Dysplasia results in 1H26 for TN-401 More Info: https://pryzm.ozmosi.com/product/25601 https://pryzm.ozmosi.com/product/25601"
X Link 2026-01-12T20:32Z [----] followers, [---] engagements

"$TNYA Tenaya Therapeutics announced they will present P1 Cardiomyopathy Hypertrophic results in 1H26 for TN-201 More Info: https://pryzm.ozmosi.com/product/26351 https://pryzm.ozmosi.com/product/26351"
X Link 2026-01-12T20:32Z [----] followers, [---] engagements

"$ARMP -4.47% today Armata Pharmaceuticals Announces End-of-Phase [--] Meeting with FDA and Plans to Advance AP-SA02 to a Phase [--] Superiority Study in Complicated BacteremiaStaphylococcusaureus More Info: https://pryzm.ozmosi.com/product/25886 https://pryzm.ozmosi.com/product/25886"
X Link 2026-01-13T14:02Z [----] followers, [--] engagements

"$KTTA +nan% today Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines More Info: https://pryzm.ozmosi.com/product/25828 https://pryzm.ozmosi.com/product/25828"
X Link 2026-01-13T14:02Z [----] followers, [---] engagements

"$ORKA Oruka Therapeutics announced they will present P2 Psoriasis results in YE27 for ORKA-001 More Info: https://pryzm.ozmosi.com/product/33552 https://pryzm.ozmosi.com/product/33552"
X Link 2026-01-13T18:20Z [----] followers, [---] engagements

"$INAB IN8bio presented P1 Glioblastoma results on 2026-01-12 for INB-200 More Info: https://pryzm.ozmosi.com/product/26008 https://pryzm.ozmosi.com/product/26008"
X Link 2026-01-13T18:20Z [----] followers, [---] engagements

"$INAB IN8bio presented P2 Glioblastoma results on 2026-01-12 for INB-400 More Info: https://pryzm.ozmosi.com/product/26928 https://pryzm.ozmosi.com/product/26928"
X Link 2026-01-13T18:20Z [----] followers, [---] engagements

"$LXEO Lexeo Therapeutics presented P1 Arrhythmogenic Cardiomyopathies results on 2026-01-12 for LX-2020 More Info: https://pryzm.ozmosi.com/product/30483 https://pryzm.ozmosi.com/product/30483"
X Link 2026-01-13T18:20Z [----] followers, [---] engagements

"$ORKA Oruka Therapeutics presented P1 Healthy Volunteers results on 2026-01-12 for ORKA-002 More Info: https://pryzm.ozmosi.com/product/34383 https://pryzm.ozmosi.com/product/34383"
X Link 2026-01-13T18:20Z [----] followers, [---] engagements

"$CCCC C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways More Info: https://pryzm.ozmosi.com/product/21073 https://pryzm.ozmosi.com/product/21073"
X Link 2026-01-14T14:02Z [----] followers, [---] engagements

"$KTTA Pasithea Therapeutics announced they will present P1 Neurofibroma Plexiform results in 2H26 for PAS-004 More Info: https://pryzm.ozmosi.com/product/25828 https://pryzm.ozmosi.com/product/25828"
X Link 2026-01-14T18:20Z [----] followers, [---] engagements

"$ANRO Alto Neuroscience presented P2 AnhedoniaDepressive Disorder Major results on 2026-01-13 for ALTO-203 More Info: https://pryzm.ozmosi.com/product/27727 https://pryzm.ozmosi.com/product/27727"
X Link 2026-01-14T18:20Z [----] followers, [---] engagements

"$CCCC C4 Therapeutics announced they will present P2 Multiple Myeloma results in 2H27 for Cemsidomide More Info: https://pryzm.ozmosi.com/product/21073 https://pryzm.ozmosi.com/product/21073"
X Link 2026-01-15T18:20Z [----] followers, [---] engagements

"$NBIX Neurocrine presented P2 Tardive Dyskinesia results on 2026-01-15 for Valbenazine More Info: https://pryzm.ozmosi.com/product/2327 https://pryzm.ozmosi.com/product/2327"
X Link 2026-01-16T18:20Z [----] followers, [---] engagements

"$OSTX OS Therapies presented P2 Osteosarcoma results on 2026-01-15 for OST31-164 More Info: https://pryzm.ozmosi.com/product/23166 https://pryzm.ozmosi.com/product/23166"
X Link 2026-01-16T18:20Z [--] followers, [---] engagements

"$BOLD Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway More Info: https://pryzm.ozmosi.com/product/36181 https://pryzm.ozmosi.com/product/36181"
X Link 2026-01-20T14:02Z [----] followers, [---] engagements

"$DYN Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type [--] More Info: https://pryzm.ozmosi.com/product/26167 https://pryzm.ozmosi.com/product/26167"
X Link 2026-01-20T14:02Z [----] followers, [---] engagements

"$LTRN Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas More Info: https://pryzm.ozmosi.com/product/26464 https://pryzm.ozmosi.com/product/26464"
X Link 2026-01-20T14:02Z [----] followers, [---] engagements

"$NSRX Nasus Pharma Announces Positive Interim Results from Phase [--] Clinical Study of NS002 Intranasal Epinephrine Powder More Info: https://pryzm.ozmosi.com/product/36910 https://pryzm.ozmosi.com/product/36910"
X Link 2026-01-20T14:02Z [----] followers, [---] engagements

"$IVVD Invivyd and SPEAR Study Group Announce Plan for Phase [--] Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 More Info: https://pryzm.ozmosi.com/product/33169 https://pryzm.ozmosi.com/product/33169"
X Link 2026-01-20T14:02Z [----] followers, [---] engagements

"$IONS DAWNZERA (donidalorsen) approved in the European Union for hereditary angioedema (HAE) More Info: https://pryzm.ozmosi.com/product/20981 https://pryzm.ozmosi.com/product/20981"
X Link 2026-01-21T14:02Z [----] followers, [---] engagements

"$ACTU Actuate Therapeutics Announces Plans to Expand Clinical Pipeline Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers More Info: https://pryzm.ozmosi.com/product/22019 https://pryzm.ozmosi.com/product/22019"
X Link 2026-01-21T14:02Z [----] followers, [---] engagements

"$LEGN Legend Biotech to Present CARVYKTI Data at [----] Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use More Info: https://pryzm.ozmosi.com/product/20124 https://pryzm.ozmosi.com/product/20124"
X Link 2026-01-21T14:02Z [----] followers, [---] engagements

"$ARTV Artiva Biotherapeutics Announces Upcoming Presentations at the [----] Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL More Info: https://pryzm.ozmosi.com/product/23411 https://twitter.com/i/web/status/2013975510259568933 https://pryzm.ozmosi.com/product/23411 https://twitter.com/i/web/status/2013975510259568933"
X Link 2026-01-21T14:02Z [----] followers, [---] engagements

"$WALD Obagi Medical Unveils ALOHA Program to Launch Obagi saypha MagIQ Pioneering the Largest Real-World Evaluation of a New Hyaluronic Acid Filler More Info: https://pryzm.ozmosi.com/product/19391 https://pryzm.ozmosi.com/product/19391"
X Link 2026-01-21T14:02Z [----] followers, [---] engagements

"$NSRX Nasus Pharma presented P2 Anaphylaxis results on 2026-01-20 for FMXIN-002 More Info: https://pryzm.ozmosi.com/product/36910 https://pryzm.ozmosi.com/product/36910"
X Link 2026-01-21T18:20Z [----] followers, [---] engagements

"$AB AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until [----] More Info: https://pryzm.ozmosi.com/product/1289 https://pryzm.ozmosi.com/product/1289"
X Link 2026-01-21T21:02Z [----] followers, [---] engagements

"$TARA Protara Therapeutics to Present Updated Interim Data from Phase [--] ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium More Info: https://pryzm.ozmosi.com/product/23637 https://pryzm.ozmosi.com/product/23637"
X Link 2026-01-22T14:02Z [----] followers, [---] engagements

"$ALGS Aligos announced they will present P2 Hepatitis B Chronic results in YE27 for ALG-000184 More Info: https://pryzm.ozmosi.com/product/21547 https://pryzm.ozmosi.com/product/21547"
X Link 2026-01-22T18:20Z [----] followers, [---] engagements

"$TARA Protara Therapeutics announced they will present P2 Muscle CancerBladder Cancer results on 2026-02-27 for TARA-002 More Info: https://pryzm.ozmosi.com/product/23637 https://pryzm.ozmosi.com/product/23637"
X Link 2026-01-23T18:20Z [----] followers, [---] engagements

"$LBRX LB Pharmaceuticals Initiates Phase [--] ILLUMINATE-1 Trial in Bipolar Depression Expanding LB-102 Development Program More Info: https://pryzm.ozmosi.com/product/96 https://pryzm.ozmosi.com/product/96"
X Link 2026-01-26T14:02Z [----] followers, [---] engagements

"$MIST Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) More Info: https://pryzm.ozmosi.com/product/825 https://pryzm.ozmosi.com/product/825"
X Link 2026-01-26T14:02Z [----] followers, [---] engagements

"$NERV Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia on February [--] [----] More Info: https://pryzm.ozmosi.com/product/16270 https://pryzm.ozmosi.com/product/16270"
X Link 2026-01-26T14:02Z [----] followers, [---] engagements

"$CGTX Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"
X Link 2026-01-27T14:02Z [----] followers, [---] engagements

"$LGVN Longeveron announced they will present P2 Hypoplastic Left Heart Syndrome results in 3Q26 for Laromestrocel More Info: https://pryzm.ozmosi.com/product/28009 https://pryzm.ozmosi.com/product/28009"
X Link 2026-01-27T18:20Z [----] followers, [---] engagements

"$IMMX Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 More Info: https://pryzm.ozmosi.com/product/28115 https://pryzm.ozmosi.com/product/28115"
X Link 2026-01-28T14:02Z [----] followers, [---] engagements

"$CRDF Cardiff Oncology presented P2 Colorectal Cancer results on 2026-01-27 for FOLFOX More Info: https://pryzm.ozmosi.com/product/19487 https://pryzm.ozmosi.com/product/19487"
X Link 2026-01-28T18:20Z [----] followers, [---] engagements

"$SGMT Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40) a First-in-Class Once-Daily Oral FASN Inhibitor for Acne More Info: https://pryzm.ozmosi.com/product/15042 https://pryzm.ozmosi.com/product/15042"
X Link 2026-01-29T14:02Z [----] followers, [---] engagements

"$KYMR Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621 a First-in-Class Oral STAT6 Degrader More Info: https://pryzm.ozmosi.com/product/32322 https://pryzm.ozmosi.com/product/32322"
X Link 2026-01-29T14:02Z [----] followers, [---] engagements

"$UNCY Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission More Info: https://pryzm.ozmosi.com/product/33424 https://pryzm.ozmosi.com/product/33424"
X Link 2026-01-29T14:02Z [----] followers, [---] engagements

"$RVMD Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127 a RAS(ON) G12V-Selective Inhibitor More Info: https://pryzm.ozmosi.com/product/32673 https://pryzm.ozmosi.com/product/32673"
X Link 2026-01-29T14:02Z [----] followers, [---] engagements

"$PDSB PDS Biotech presented P2 Prostate Cancer results on 2026-01-28 for PDS-0101 More Info: https://pryzm.ozmosi.com/product/24532 https://pryzm.ozmosi.com/product/24532"
X Link 2026-01-29T18:20Z [----] followers, [---] engagements

"$AB AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer More Info: https://pryzm.ozmosi.com/product/1289 https://pryzm.ozmosi.com/product/1289"
X Link 2026-01-29T21:02Z [----] followers, [---] engagements

"$SNY Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease More Info: https://pryzm.ozmosi.com/product/11397 https://pryzm.ozmosi.com/product/11397"
X Link 2026-01-30T14:02Z [----] followers, [---] engagements

"$INCY Incyte Announces Positive CHMP Opinion for Zynyz (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) More Info: https://pryzm.ozmosi.com/product/18479 https://pryzm.ozmosi.com/product/18479"
X Link 2026-01-30T15:02Z [----] followers, [---] engagements

"$DNLI Denali Therapeutics announced they will present P1 Mucopolysaccharidosis II results on 2026-02-05 for Tividenofusp alfa More Info: https://pryzm.ozmosi.com/product/22737 https://pryzm.ozmosi.com/product/22737"
X Link 2026-01-30T18:20Z [----] followers, [---] engagements

"$KYMR Kymera Therapeutics announced they will present P2 Asthma results in 2H27 for KT-621 More Info: https://pryzm.ozmosi.com/product/32322 https://pryzm.ozmosi.com/product/32322"
X Link 2026-01-30T18:20Z [----] followers, [---] engagements

"$KYMR Kymera Therapeutics announced they will present P2 Dermatitis Atopic results in 3Q27 for KT-621 More Info: https://pryzm.ozmosi.com/product/32322 https://pryzm.ozmosi.com/product/32322"
X Link 2026-01-30T18:20Z [----] followers, [---] engagements

"$SGMT Sagimet presented P3 Acne Vulgaris results on 2026-01-29 for Denifanstat More Info: https://pryzm.ozmosi.com/product/15042 https://pryzm.ozmosi.com/product/15042"
X Link 2026-01-30T18:20Z [----] followers, [---] engagements

"$PHAR Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja (leniolisib) in children aged [--] to [--] years with APDS More Info: https://pryzm.ozmosi.com/product/1183 https://pryzm.ozmosi.com/product/1183"
X Link 2026-02-01T21:02Z [----] followers, [---] engagements

"$SGMT +5.50% today Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase [--] Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne More Info: https://pryzm.ozmosi.com/product/15042 https://pryzm.ozmosi.com/product/15042"
X Link 2026-02-02T14:02Z [----] followers, [---] engagements

"$WVE -0.46% today Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency More Info: https://pryzm.ozmosi.com/product/27387 https://pryzm.ozmosi.com/product/27387"
X Link 2026-02-02T14:02Z [----] followers, [---] engagements

"$IGC -0.53% today IGC Pharma Reaches 70% Enrollment in Phase [--] CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation More Info: https://pryzm.ozmosi.com/product/25988 https://pryzm.ozmosi.com/product/25988"
X Link 2026-02-02T14:02Z [----] followers, [---] engagements

"$MLTX -3.27% today MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day More Info: https://pryzm.ozmosi.com/product/20826 https://pryzm.ozmosi.com/product/20826"
X Link 2026-02-02T14:02Z [----] followers, [---] engagements

"$SNY +1.76% today Press Release: Sanofi's venglustat met all primary endpoints in a phase [--] study of type [--] Gaucher disease More Info: https://pryzm.ozmosi.com/product/8420 https://pryzm.ozmosi.com/product/8420"
X Link 2026-02-02T14:02Z [----] followers, [---] engagements

"$EXEL -2.14% today Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer More Info: https://pryzm.ozmosi.com/product/19713 https://pryzm.ozmosi.com/product/19713"
X Link 2026-02-02T14:02Z [----] followers, [---] engagements

"$RLAY +6.19% today Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant HR+/HER2- Advanced Breast Cancer More Info: https://pryzm.ozmosi.com/product/25143 https://pryzm.ozmosi.com/product/25143"
X Link 2026-02-03T14:02Z [----] followers, [---] engagements

"$MIRA -3.38% today MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase [--] Clinical Study as Company Prepares for Phase 2a Study More Info: https://pryzm.ozmosi.com/product/31932 https://pryzm.ozmosi.com/product/31932"
X Link 2026-02-03T14:02Z [----] followers, [---] engagements

"$GTBP +nan% today GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 More Info: https://pryzm.ozmosi.com/product/25796 https://pryzm.ozmosi.com/product/25796"
X Link 2026-02-03T14:02Z [----] followers, [---] engagements

"$IVVD -0.57% today Invivyd Aligns with the U.S. FDA on LIBERTY a Phase [--] Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration More Info: https://pryzm.ozmosi.com/product/33169 https://pryzm.ozmosi.com/product/33169"
X Link 2026-02-03T14:02Z [----] followers, [---] engagements

"$SNY +0.52% today Rezurock now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD) More Info: https://pryzm.ozmosi.com/product/11397 https://pryzm.ozmosi.com/product/11397"
X Link 2026-02-03T14:02Z [----] followers, [---] engagements

"$ALUR Allurion Announces Partnership to Offer Combination Therapy with Mounjaro (tirzepatide) at Discounted Prices More Info: https://pryzm.ozmosi.com/product/18435 https://pryzm.ozmosi.com/product/18435"
X Link 2026-02-03T15:02Z [----] followers, [---] engagements

"$TEVA Teva Canada Announces Approval of Expanded Indication of PrAJOVY (fremanezumab solution for subcutaneous injection) the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine More Info: https://pryzm.ozmosi.com/product/10812 https://pryzm.ozmosi.com/product/10812"
X Link 2026-02-04T14:02Z [----] followers, [---] engagements

"$BMY Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi More Info: https://pryzm.ozmosi.com/product/17479 https://pryzm.ozmosi.com/product/17479"
X Link 2026-02-04T14:02Z [----] followers, [---] engagements

"$ACLX +nan% today Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique High Target-Specificity of anito-cel's D-Domain Binder More Info: https://pryzm.ozmosi.com/product/27164 https://pryzm.ozmosi.com/product/27164"
X Link 2026-02-04T15:02Z [----] followers, [---] engagements

"$AMGN Amgen announced they will present P3 Sjogren's Syndrome results in 2H26 for Dazodalibep More Info: https://pryzm.ozmosi.com/product/17541 https://pryzm.ozmosi.com/product/17541"
X Link 2026-02-04T18:20Z [----] followers, [---] engagements

"$IVVD Invivyd announced they will present P3 COVID-19 results in 3Q26 for VYD-2311 More Info: https://pryzm.ozmosi.com/product/33169 https://pryzm.ozmosi.com/product/33169"
X Link 2026-02-04T18:20Z [----] followers, [---] engagements

"$RLAY Relay Therapeutics announced they will present P3 Breast Cancer results on 2026-03-16 for Zovegalisib More Info: https://pryzm.ozmosi.com/product/25143 https://pryzm.ozmosi.com/product/25143"
X Link 2026-02-04T18:20Z [----] followers, [---] engagements

"$CGTX Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies More Info: https://pryzm.ozmosi.com/product/17378 https://pryzm.ozmosi.com/product/17378"
X Link 2026-02-05T14:02Z [----] followers, [---] engagements

"$RNAZ TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 More Info: https://pryzm.ozmosi.com/product/26544 https://pryzm.ozmosi.com/product/26544"
X Link 2026-02-05T14:02Z [----] followers, [---] engagements

"$ALVO Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio More Info: https://pryzm.ozmosi.com/product/8410 https://pryzm.ozmosi.com/product/8410"
X Link 2026-02-05T14:02Z [----] followers, [---] engagements

"$CANF Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson More Info: https://pryzm.ozmosi.com/product/19867 https://pryzm.ozmosi.com/product/19867"
X Link 2026-02-05T14:02Z [----] followers, [---] engagements

"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"
X Link 2026-02-05T14:02Z [----] followers, [---] engagements

"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"
X Link 2026-02-05T14:02Z [----] followers, [---] engagements

"$ACLX Arcellx announced they will present P0 Multiple Myeloma results on 2026-02-05 for Anitocabtagene autoleucel More Info: https://pryzm.ozmosi.com/product/27164 https://pryzm.ozmosi.com/product/27164"
X Link 2026-02-05T18:20Z [----] followers, [---] engagements

"$CRBU Caribou Biosciences announced they will present P1 Lymphoma Non-HodgkinLymphoma B-Cell results on 2026-02-05 for Vispacabtagene regedleucel More Info: https://pryzm.ozmosi.com/product/22257 https://pryzm.ozmosi.com/product/22257"
X Link 2026-02-05T18:20Z [----] followers, [---] engagements

"$CRBU Caribou Biosciences announced they will present P1 Multiple Myeloma results on 2026-02-07 for CB-011 More Info: https://pryzm.ozmosi.com/product/26508 https://pryzm.ozmosi.com/product/26508"
X Link 2026-02-05T18:20Z [----] followers, [---] engagements

"$BIIB Biogen presented P3 Muscular Atrophy Spinal results on 2026-02-04 for Nusinersen More Info: https://pryzm.ozmosi.com/product/1525 https://pryzm.ozmosi.com/product/1525"
X Link 2026-02-05T18:20Z [----] followers, [---] engagements

"$BAYRY Bayer's Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack With No Increase in ISTH Major Bleeding Versus Placebo More Info: https://pryzm.ozmosi.com/product/22569 https://pryzm.ozmosi.com/product/22569"
X Link 2026-02-05T21:02Z [----] followers, [---] engagements

"$ROIV Roivant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December [--] [----] More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"
X Link 2026-02-06T14:02Z [----] followers, [---] engagements

"$ROIV Priovant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"
X Link 2026-02-06T14:02Z [----] followers, [---] engagements

"$QURE uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in -Gal A Enzyme Activity in Patients with Fabry Disease More Info: https://pryzm.ozmosi.com/product/26583 https://pryzm.ozmosi.com/product/26583"
X Link 2026-02-06T14:02Z [----] followers, [---] engagements

"$OCUL Ocular Therapeutix announced they will present P3 Wet Macular Degeneration results in 1Q26 for OTX-TKI More Info: https://pryzm.ozmosi.com/product/30592 https://pryzm.ozmosi.com/product/30592"
X Link 2026-02-06T18:20Z [----] followers, [---] engagements

"$DNLI Denali Therapeutics presented P0 Glycogen Storage Disease Type II results on 2026-02-05 for DNL-952 More Info: https://pryzm.ozmosi.com/product/37259 https://pryzm.ozmosi.com/product/37259"
X Link 2026-02-06T18:20Z [----] followers, [---] engagements

"$DNLI Denali Therapeutics presented P1 Mucopolysaccharidosis II results on 2026-02-05 for Tividenofusp alfa More Info: https://pryzm.ozmosi.com/product/22737 https://pryzm.ozmosi.com/product/22737"
X Link 2026-02-06T18:20Z [----] followers, [---] engagements

"$DNLI Denali Therapeutics presented P1 Mucopolysaccharidosis III results on 2026-02-05 for DNL-126 More Info: https://pryzm.ozmosi.com/product/29262 https://pryzm.ozmosi.com/product/29262"
X Link 2026-02-06T18:20Z [----] followers, [---] engagements

"$ASND Pendopharm Announces the Approval of Yorvipath (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults More Info: https://pryzm.ozmosi.com/product/32243 https://pryzm.ozmosi.com/product/32243"
X Link 2026-02-06T21:02Z [----] followers, [---] engagements

"$RHHBY Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"
X Link 2026-02-07T21:02Z [----] followers, [---] engagements

"$RHHBY Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"
X Link 2026-02-07T21:02Z [----] followers, [---] engagements

"$MANE Veradermics Completes Enrollment in Second Pivotal Phase [--] Clinical Trial of VDPHL01 for Male Pattern Hair Loss More Info: https://pryzm.ozmosi.com/product/33162 https://pryzm.ozmosi.com/product/33162"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$FDMT 4DMT Completes Enrollment for 4FRONT-1 Phase [--] Clinical Trial of 4D-150 in Wet AMD More Info: https://pryzm.ozmosi.com/product/27134 https://pryzm.ozmosi.com/product/27134"
X Link 2026-02-09T14:02Z [----] followers, [--] engagements

"$VRCA Verrica Pharmaceuticals Announces Launch of YCANTH for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical More Info: https://pryzm.ozmosi.com/product/15530 https://pryzm.ozmosi.com/product/15530"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$CMND Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial More Info: https://pryzm.ozmosi.com/product/27783 https://pryzm.ozmosi.com/product/27783"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$KRYS Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer More Info: https://pryzm.ozmosi.com/product/30849 https://pryzm.ozmosi.com/product/30849"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$CANF Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy More Info: https://pryzm.ozmosi.com/product/19867 https://pryzm.ozmosi.com/product/19867"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$ZBIO Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase [--] MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum [----] More Info: https://pryzm.ozmosi.com/product/17691 https://pryzm.ozmosi.com/product/17691"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$SNY Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia More Info: https://pryzm.ozmosi.com/product/18646 https://pryzm.ozmosi.com/product/18646"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$ESLA Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the [----] Tandem Meetings of ASTCT & CIBMTR More Info: https://pryzm.ozmosi.com/product/29687 https://pryzm.ozmosi.com/product/29687"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://pryzm.ozmosi.com/product/22745 https://pryzm.ozmosi.com/product/22745"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$SLDB Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy More Info: https://pryzm.ozmosi.com/product/26382 https://pryzm.ozmosi.com/product/26382"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$BRCTF BLA for subcutaneous formulation of Leqembi designated for Priority Review in China More Info: https://pryzm.ozmosi.com/product/16901 https://pryzm.ozmosi.com/product/16901"
X Link 2026-02-09T14:02Z [----] followers, [---] engagements

"$NRSN NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition More Info: https://pryzm.ozmosi.com/product/28154 https://pryzm.ozmosi.com/product/28154"
X Link 2026-02-09T15:02Z [----] followers, [---] engagements

"$COX +nan% today Nicox to Present Data from NCX [---] Phase [--] Studies at American Glaucoma Society (AGS) Annual Meeting [----] More Info: https://pryzm.ozmosi.com/product/23864 https://pryzm.ozmosi.com/product/23864"
X Link 2026-02-10T14:02Z [----] followers, [--] engagements

"$NKTR +0.63% today New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing More Info: https://pryzm.ozmosi.com/product/20557 https://pryzm.ozmosi.com/product/20557"
X Link 2026-02-10T14:02Z [----] followers, [---] engagements

"$PHIO +nan% today Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial More Info: https://pryzm.ozmosi.com/product/25034 https://pryzm.ozmosi.com/product/25034"
X Link 2026-02-10T14:02Z [----] followers, [---] engagements

"$MDCX -3.57% today Medicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk More Info: https://pryzm.ozmosi.com/product/2179 https://pryzm.ozmosi.com/product/2179"
X Link 2026-02-10T14:02Z [----] followers, [---] engagements

"$EVMN -3.04% today Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis More Info: https://pryzm.ozmosi.com/product/33649 https://pryzm.ozmosi.com/product/33649"
X Link 2026-02-10T14:02Z [----] followers, [---] engagements

"$AARD +6.76% today Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101 Expanding Eligibility in Phase [--] Study of Prader-Willi Syndrome More Info: https://pryzm.ozmosi.com/product/24702 https://pryzm.ozmosi.com/product/24702"
X Link 2026-02-10T14:02Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing